Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,934 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Group C Clear all
Completed No phase listed Observational

HER Salt Lake Initiative

NCT02734199
View directory record Official record
Conditions
Birth Control, Contraception
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
4,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 22, 2026, 11:23 PM EDT
Terminated Phase 4 Interventional Results available

Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage

NCT01530880
View directory record Official record
Conditions
Fever
Interventions
Intravenous Ibuprofen, Acetaminophen (Standard of Care)
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 22, 2026, 11:23 PM EDT
Completed No phase listed Observational

A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate

NCT05421299
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

NCT05765344
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Bulevirtide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 79 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
6
States / cities
Lake Forest, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 1 Interventional

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

NCT02338349
View directory record Official record
Conditions
Advanced ER+, HER2-Negative Breast Cancer
Interventions
Elacestrant
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

NCT01297543
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia
Interventions
human myeloid progenitor cells, G-CSF
Biological · Drug
Lead sponsor
Cellerant Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
La Jolla, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

Penetrating the Classroom Social Network for Children With Language Impairment Via Peer Mediated Intervention

NCT06182033
View directory record Official record
Conditions
Peer Influence
Interventions
Peer-mediated pivotal response training
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
36 Months to 66 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 22, 2026, 11:23 PM EDT
Completed No phase listed Observational

Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth

NCT01484522
View directory record Official record
Conditions
HIV-1 Infection, H1N1, Influenza, Flu
Interventions
FluMist, Fluvirin, Fluzone
Biological
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Months to 25 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2011 · Synced Oct 22, 2026, 11:23 PM EDT
Recruiting Phase 2 Interventional

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

NCT07087860
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
Other · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 11:23 PM EDT
Active, not recruiting Not applicable Interventional

Penn Medicine Food Market Study

NCT06283394
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
Storefront Choice Architecture, Fresh Funds, Loss Framing
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 22, 2026, 11:23 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 22, 2026, 11:23 PM EDT
Terminated Phase 2 Interventional

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT00801060
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lumiliximab + FCR, FCR
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Gainesville, Florida • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 22, 2026, 11:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Consumer Understanding and Use of Medication Guides

NCT01731405
View directory record Official record
Conditions
Revised Medication Guide Formats
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

NCT03712280
View directory record Official record
Conditions
Hepatic Cirrhosis, Hepatic Encephalopathy (HE)
Interventions
MNK6106, Rifaximin
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Coronado, California • Rialto, California • St. Petersburg, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 22, 2026, 11:23 PM EDT
Recruiting Not applicable Interventional

Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors

NCT06941324
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Behavioral Intervention, Best Practice, Communication Intervention, Discussion, Health Promotion and Education, Interview, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
15 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

Organizational Skills Training - Tier 2 (OST-T2)

NCT03443323
View directory record Official record
Conditions
Executive Function, Behavioral Research, Schools, Behavior Therapy
Interventions
Organizational Skills Training - Tier 2 (OST-T2)
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design

NCT04005456
View directory record Official record
Conditions
Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases, Dental Diseases, Hormone Disturbance, Neurocognitive Dysfunction
Interventions
Supplements and/or medical foods, Behavioral change support program, Food plan
Dietary Supplement · Behavioral · Other
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implementing an Intervention to Reduce Heat Stress and Chemical Exposures

NCT06442969
View directory record Official record
Conditions
Dehydration, Heat Stress
Interventions
Education and resources provided by community health workers
Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
El Centro, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 22, 2026, 11:23 PM EDT
Recruiting Phase 2 Interventional

ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer

NCT07425054
View directory record Official record
Conditions
Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus
Interventions
HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab
Radiation · Drug
Lead sponsor
Jennifer Dorth
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Study of the Effect of Two Experimental Lozenges on Oral Malodor After Single Use

NCT05950529
View directory record Official record
Conditions
Oral Malodor
Interventions
Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract, Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor, Placebo lozenge control (sorbitol only), No product
Other
Lead sponsor
Novozymes A/S
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 22, 2026, 11:23 PM EDT
Not listed Not applicable Interventional

FallsTalk Falls Prevention Program for Caregivers and Persons With Memory Loss or Dementia

NCT03961386
View directory record Official record
Conditions
Falls (Accidents) in Old Age
Interventions
FallsTalk-C, FallsTalk
Behavioral
Lead sponsor
Brookside Research & Development Company
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Freeland, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

VALES+Tú: Targeting Psychosocial Stressors to Reduce Latino Day Laborers (LDL) Injury Disparities

NCT04800757
View directory record Official record
Conditions
Work-related Injury
Interventions
individual -Brief Motivational Intervention (BMI), Group (Group Problem Solving), Standard of Care (OSHA 10 Safety Cards)
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comprehensive Communication Intervention for Minimally Verbal Children With Autism

NCT02291172
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Intervention JEP
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
36 Months to 54 Months
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 22, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

NCT00777257
View directory record Official record
Conditions
Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions
T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 17 Years
Enrollment
1,345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
20
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 22, 2026, 11:23 PM EDT